MedTrace Logo

Efficacy of Treatment Sequences in Patients With Non-small Cell Lung Cancer Receiving Lorlatinib

NCT03727477 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 291

Last updated 2023-05-24

No results posted yet for this study

Summary

The study will evaluate progression-free survival, overall survival, best response and duration of treatment in patients with advanced ALK- and ROS1-positive non-small cell lung cancer who received lorlatinib as part of the French expanded access program.

Conditions

  • Non-small Cell Lung Cancer Metastatic
  • ALK Gene Rearrangement Positive
  • ROS-1 Gene Rearrangement Positive

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • Intergroupe Francophone de Cancerologie Thoracique

    lead OTHER

Principal Investigators

  • Nicolas Girard, MD, PhD · Institut Curie Paris

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-02-01
Primary Completion
2020-10-12
Completion
2020-10-12

Countries

  • France

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03727477 on ClinicalTrials.gov